Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Press Release

Evaluate Ltd Named In “Ones to Recognise” Category in Sunday Times Annual BDO Profit Track 100

Download PDF

LONDON, BOSTON, TOKYO (April 11, 2016) — Life science market intelligence firm, Evaluate Ltd today announces that it has been selected as one of 10 companies in the “Ones to Recognise” category in the Sunday Times 17th Annual BDO Profit Track 100.

The “Ones to Recognise” group represents the best of the companies selected for the Profit Track 100 main category but this year did not meet the category’s financial criteria. However, these companies are viewed to have shown excellent past profits and forecast further rapid financial growth.

Jonathan de Pass, Chairman and Founder of Evaluate, said: “Being named in this category is an endorsement of our staff’s dedication to rapidly and profitably growing the business by making Evaluate’s products essential for the life sciences marketplace. It is an honour to be recognised by BDO and the Sunday Times as a business to watch.”


About Evaluate Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Evaluate Custom Services provides project-based analytical and data services. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

For more information visit: www.evaluategroup.com.

On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

Back to Press Releases